Myeloid cell surface antigen CD33, is a transmembrane receptor expressed on cells of myeloid lineage. It has numerous synonymous names including Siglec-3, sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67 or p67. CD33 is broadly expressed on acute myeloid leukemia (AML) blasts and, possibly some leukemic stem cells and has therefore been exploited as target for therapeutic antibodies. Some antibody-drug conjugates such as gemtuzumab ozogamicin target at CD33 for the treatment of patients with acute myeloid leukemia.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE